We demonstrate the immunomodulatory effects of an anti-CD38 antibody in vivo (a decrease in immune suppressor cells) and show that targeting two pathways, CD38 and PD-1, can result in enhanced anti-tumor effects vs. either pathway alone. Here, PDCD1 is linked to neoplasm.